ISK Ltd is a resident company of Johnson & Johnson Innovation – JLABS, a premier life science incubator program.
JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps
ISK is proud to announce a significant development in our ongoing commitment to cancer research and treatment. We have successfully developed and are now in the process of filing a patent for an enhanced form of Nerofe, our proprietary cancer treatment.
This advancement represents a major milestone in our mission to combat cancer. The enhanced form
ISK is excited to report the official opening of its second FDA approved clinical trial in the US in patients with pancreatic cancer and metastatic colorectal cancer at Georgetown University in Washington, D.C.
Following FDA approval to open our trial at Georgetown University in Washington DC, we received final IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track
Using a new formulation of Nerofe, treating a patient with Stage 4 squamous cell lung cancer (positive for ST2), caused the complete disappearance of some tumors and a decrease in the size of other tumors. Increase in hepatic function.
Using a new formulation of Nerofe on a patient (positive for ST2) with adenocarcinoma in the anus and two metastasis in the peritoneum caused the complete disappearance of tumors.
ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC
No side effects were recorded
Who is entitled to enroll in the trial:
AML /Hi-Risk MDS patients with:
8 weeks of life expectancy.
clinically deteriorating.
have no more available treatments.
In cohort 1 (dose=6mg/m^2) three patients were enrolled.
The first patient was alive with this dose for 5 months.
The second patient was alive with this dose for 1.5 months.
The third
